Investments	12 Months Ended
Dec. 31, 2023
Investments
Investments	4. Investments At December 31, 2023 and 2022, the Company owns -0- and 8,238,769 shares respectively, of common stock of Medical Cannabis Payment Solutions (ticker: REFG). At December 31, 2023 and 2022, the fair value of the investment in REFG was $-0- and $12,358, respectively. The Company recognized a loss on the change in fair value of $-0- and $13,182 during the years ended December 31, 2023 and 2022, respectively. In January 2023, the Company sold all of its holdings in REFG for $9,041 and recognized a gain of $155,735. In 2021, the Company received 1,500,000 shares of common stock and 1,500,000 shares of preferred stock of THC Pharmaceuticals Inc. (ticker: CBDG). The CBDG shares were received as consideration for the sale of the Company’s majority interest in iBud and GKMP in the year ended December 31, 2021. On the date of sale, the shares were valued at fair value which was $0.20 per share or $600,000 in the aggregate. The Company’s Chief Executive Officer and Chairman of the Board, David Tobias is a Director of CBDG. The Company’s investment in CBDG represents 15% of CBDG’s voting shares on a fully diluted basis which, coupled with Mr. Tobias’ position as a director and his individual investment in CBDG, results in the Company having significant influence over CBDG. The Company elected to account for its investment in CBDG at fair value because the Company does not intend to hold the investment for a long period of time and the shares are readily marketable. The fair value of the Company’s investment at December 31, 2023 and December 31, 2022 was $66,000 and $367,500 resulting in a gain (loss) of $(301,500) and $184,500 for the change in fair value during the years ended December 31, 2023 and 2022, respectively.

Investments

12 Months Ended

Dec. 31, 2023

4. Investments

At December 31, 2023 and 2022, the Company owns -0- and 8,238,769 shares respectively, of common stock of Medical Cannabis Payment Solutions (ticker: REFG). At December 31, 2023 and 2022, the fair value of the investment in REFG was $-0- and $12,358, respectively. The Company recognized a loss on the change in fair value of $-0- and $13,182 during the years ended December 31, 2023 and 2022, respectively. In January 2023, the Company sold all of its holdings in REFG for $9,041 and recognized a gain of $155,735.

In 2021, the Company received 1,500,000 shares of common stock and 1,500,000 shares of preferred stock of THC Pharmaceuticals Inc. (ticker: CBDG). The CBDG shares were received as consideration for the sale of the Company’s majority interest in iBud and GKMP in the year ended December 31, 2021. On the date of sale, the shares were valued at fair value which was $0.20 per share or $600,000 in the aggregate. The Company’s Chief Executive Officer and Chairman of the Board, David Tobias is a Director of CBDG.

The Company’s investment in CBDG represents 15% of CBDG’s voting shares on a fully diluted basis which, coupled with Mr. Tobias’ position as a director and his individual investment in CBDG, results in the Company having significant influence over CBDG. The Company elected to account for its investment in CBDG at fair value because the Company does not intend to hold the investment for a long period of time and the shares are readily marketable. The fair value of the Company’s investment at December 31, 2023 and December 31, 2022 was $66,000 and $367,500 resulting in a gain (loss) of $(301,500) and $184,500 for the change in fair value during the years ended December 31, 2023 and 2022, respectively.